Evidence map›Paper›PMID 37917177›Full record

ArticleJCI insight2023

A molecular signature for IL-10-producing Th1 cells in protozoan parasitic diseases.

Chelsea L Edwards, Jessica A Engel, Fabian de Labastida Rivera, Susanna S Ng, Dillon Corvino, Marcela Montes de Oca, Teija Cm Frame, Shashi Bhushan Chauhan, Siddharth Sankar Singh, Awnish Kumar and 8 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Leishmaniasis.Nature reviews. Disease primers · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. The role of CD4Frontiers in cellular and infection microbiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 4 countries.

Chelsea L EdwardsQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Jessica A EngelQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Fabian de Labastida RiveraQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Susanna S NgQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Dillon CorvinoQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Marcela Montes de OcaQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Teija Cm FrameQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Shashi Bhushan ChauhanInstitute of Medical Sciences and.
Siddharth Sankar SinghInstitute of Medical Sciences and.
Awnish KumarCentre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Yulin WangQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Jinrui NaQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Pam MukhopadhyayQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Jason S LeeQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Susanne NylenDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Shyam SundarInstitute of Medical Sciences and.
Rajiv KumarCentre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Christian R EngwerdaQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Institute of Medical Sciences · INQIMR Berghofer Medical Research Institute · AUThe University of Queensland · AUGriffith University · AUKarolinska Institutet · SEUniversity of Bonn · DE

Funding

Visceral Leishmaniasis in Bihar State, IndiaU19AI074321 · NIAID · BANARAS HINDU UNIVERSITY · PI SUNDAR, SHYAM · 2017 to 2021
$2.8M
NIAID NIH HHS U19 AI074321
6 · The paper itself

Abstract

Control of visceral leishmaniasis (VL) depends on proinflammatory Th1 cells that activate infected tissue macrophages to kill resident intracellular parasites. However, proinflammatory cytokines produced by Th1 cells can damage tissues and require tight regulation. Th1 cell IL-10 production is an important cell-autologous mechanism to prevent such damage. However, IL-10-producing Th1 (type 1 regulatory; Tr1) cells can also delay control of parasites and the generation of immunity following drug treatment or vaccination. To identify molecules to target in order to alter the balance between Th1 and Tr1 cells for improved antiparasitic immunity, we compared the molecular and phenotypic profiles of Th1 and Tr1 cells in experimental VL caused by Leishmania donovani infection of C57BL/6J mice. We also identified a shared Tr1 cell protozoan signature by comparing the transcriptional profiles of Tr1 cells from mice with experimental VL and malaria. We identified LAG3 as an important coinhibitory receptor in patients with VL and experimental VL, and we reveal tissue-specific heterogeneity of coinhibitory receptor expression by Tr1 cells. We also discovered a role for the transcription factor Pbx1 in suppressing CD4+ T cell cytokine production. This work provides insights into the development and function of CD4+ T cells during protozoan parasitic infections and identifies key immunoregulatory molecules.

Indexed as

Interleukin-10Protozoan InfectionsTh1 CellsAnimalsCD4-Positive T-LymphocytesDisease Models, AnimalHumansInterferon-gammaLeishmania donovaniLeishmaniasis, VisceralLymphocyte Activation Gene 3 ProteinMiceMice, Inbred C57BLPre-B-Cell Leukemia Transcription Factor 1Promoter Regions, GeneticProtein BindingInterferon-gammaInterleukin-10Lymphocyte Activation Gene 3 ProteinPre-B-Cell Leukemia Transcription Factor 1MicrobiologyT cells

Identifiers

PMID37917177
PMCPMC10807716
OpenAlexW4388220274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.